HC Wainwright Analysts Give RedHill Biopharma Ltd. (RDHL) a $33.00 Price Target
RedHill Biopharma Ltd. (NASDAQ:RDHL) received a $33.00 price target from analysts at HC Wainwright in a research report issued on Friday. The firm currently has a a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 139.30% from the stock’s previous close.
RDHL has been the subject of several other reports. Zacks Investment Research raised shares of RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Friday, August 26th. FBR & Co raised their price objective on shares of RedHill Biopharma from $33.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, July 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up 0.0674% on Friday, hitting $13.7993. 34,793 shares of the stock traded hands. The firm’s market cap is $175.72 million. The stock has a 50-day moving average price of $14.75 and a 200 day moving average price of $12.75. RedHill Biopharma has a 52 week low of $8.10 and a 52 week high of $16.54.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/hc-wainwright-analysts-give-redhill-biopharma-ltd-rdhl-a-33-00-price-target.html
RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.52. Equities research analysts predict that RedHill Biopharma will post ($2.06) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in RDHL. Van ECK Associates Corp increased its position in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of RedHill Biopharma during the second quarter valued at approximately $142,000. Royal Bank of Canada increased its position in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Finally, Ingalls & Snyder LLC purchased a new position in shares of RedHill Biopharma during the second quarter valued at approximately $451,000. 15.30% of the stock is owned by hedge funds and other institutional investors.
About RedHill Biopharma
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.